Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High – Should You Buy?

Roivant Sciences Ltd. (NASDAQ:ROIV) hit a new 52-week high on Tuesday . The company traded as high as $41.62 and last traded at $39.0310, with a volume of 710937 shares trading hands. The stock had previously closed at $34.93.

Analysts Set New Price Targets

ROIV has been the subject of a number of research reports. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. HC Wainwright restated a “buy” rating and issued a $41.00 price target on shares of Roivant Sciences in a research note on Friday, August 28th. Citigroup increased their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Tuesday, August 25th. Finally, Guggenheim increased their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Roivant Sciences Trading Up 14.1%

The business’s fifty day moving average price is $35.30 and its 200 day moving average price is $31.26. The firm has a market capitalization of $28.79 billion, a price-to-earnings ratio of -75.20 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The firm had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Insider Transactions at Roivant Sciences

In other news, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider directly owned 18,630,739 shares in the company, valued at $675,364,288.75. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Gold sold 800,000 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the sale, the director owned 13,701,546 shares in the company, valued at $473,388,414.30. This represents a 5.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055,913 shares of company stock valued at $107,261,258 in the last 90 days. 8.80% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Morgan Stanley boosted its position in Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Rubric Capital Management LP raised its holdings in shares of Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after purchasing an additional 2,603,260 shares during the period. State Street Corp grew its position in shares of Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after buying an additional 911,827 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Roivant Sciences by 4,212.2% in the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock worth $672,448,000 after acquiring an additional 18,560,434 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after acquiring an additional 8,621,567 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.